In Myc-amplified small-cell lung cancer, ML (commercial preparation from Sigma-Aldrich, Saint Louis, MO, USA) specifically decreased expression of amplified C-myc and N-myc proteins, with overexpression of either myc variant paradoxically enhancing cellular sensitivity to treatment [50]. The gene discussed is MYC; the disease is small cell lung carcinoma.